Btc burn
bc1qrvv7m6a63tfa0cclf8su77ajhkczcmy4w0t34n
Eth burn
0x0EE385C511B3a706c4648aF7A064c0452A2d6C7e
Sol burning
6WLwGnFA2YWr9Dfj3zoCz5N5xx5x9Li6WpWtAhdRt15R
All the titles lead to my wallet, burn them very quietly
#btc#eth#sol#Bitcoin
$HOTH +11.7% [HT-KIT, a new cancer drug, shows powerful tumor-killing ability in models within 24 hours, has a clean safety profile, and exceeds regulatory validation standards. It aims to treat KIT-driven cancers and is moving toward human trials.] https://t.co/FpiuZQhZGL
$BTAI
Dr. Frank D. Yocca served as Vice President & Head of CNS & Pain Drug Discovery at AstraZeneca ( $AZN) and as Executive Director of Neuroscience at Bristol-Myers Squibb ( $BMY), where he was recognized as a key R&D leader in the development of several prominent CNS drugs, including:
1.Buspar – an anxiolytic for generalized anxiety disorder
2.Serzone – an antidepressant for major depressive disorder
3.Abilify – an atypical antipsychotic for schizophrenia, bipolar disorder, and adjunctive treatment of depression
4.Hetlioz – a treatment for non-24-hour sleep-wake disorder
He is widely acknowledged as a core scientific contributor to these neuroscience therapies.